Xeomin

Merz’s Xeomin is distinguished by its lack of accessory proteins, a feature that reduces the risk of developing antibodies against the treatment, making it an excellent option for regular users. Approved by the FDA in 2011, Xeomin offers a purer form of botulinum toxin. It begins working within a week and also has a three-month duration of effect. Xeomin is particularly suited for individuals looking for a straightforward, effective treatment with minimal additives.